International forskning

Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation

Ellen A Oseni 1, Miriam Blumenthal 1, Stephanie Izard 2, Michael Qiu 2, Anjali Mone 3, Arun Swaminath 3, Keith Sultan 1

  • 1Division of Gastroenterology, Northshore University Hospital, Manhasset, NY, USA.
  • 2Center for Health Innovations and Outcomes Research, Feinstein Institutes for Medical Research, Manhasset, NY, USA.
  • 3Division of Gastroenterology, Lenox Hill Hospital, New York, NY, USA.


Background: Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal was to examine the relationship between cannabis use and the risk of 30- and 90-day hospital readmissions.

Methods: We conducted a review of all adults admitted for an IBD exacerbation from January 1, 2016 to March 1, 2020 within the Northwell Health Care system. Patients with an IBD exacerbation were identified by primary or secondary ICD10 code (K50.xx or K51.xx) and administration of intravenous (IV) solumedrol and/or biologic therapy. Admission documents were reviewed for the terms “marijuana”, “cannabis”, “pot” and “CBD”.

Results: A total of 1,021 patient admissions met inclusion criteria, of whom 484 (47.40%) had Crohn’s disease (CD) and 542 (53.09%) were female. Pre-admission cannabis use was reported by 74 (7.25%) patients. Factors found to be associated with cannabis use included younger age, male gender, African American/Black race, current tobacco and former alcohol use, anxiety, and depression. Cannabis use was found to be associated with 30-day readmission among patients with ulcerative colitis (UC), but not among patients with CD, after respectively adjusting each final model by other factors (odds ratio (OR): 2.48, 95% confidence interval (CI): 1.06 – 5.79 and OR: 0.59, 95% CI: 0.22 – 1.62, respectively). Cannabis use was not found to be associated with 90-day readmission on univariable analysis (OR: 1.11, 95% CI: 0.65 – 1.87) nor in the final multivariable model after adjusting for other factors (OR: 1.19, 95% CI: 0.68 – 2.05).

Conclusion: Pre-admission cannabis use was found to be associated with 30-day readmission among patients with UC, but not with 30-day readmission for patients with CD nor with 90-day readmission, following an IBD exacerbation.

Keywords: Cannabis; Crohn’s disease; Inflammatory bowel disease; Opioids; Ulcerative colitis.